18 completed, 2 recruiting, 1 active not recruiting, 1 unknown. 10 Phase 2, 4 Not applicable, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Active not recruiting 1, Recruiting 1 |
| Not applicable | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow Myeloproliferative Disorder: new trials by email Literature Review of Myeloproliferative Disorder trials Research Report on Myeloproliferative Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia Gene sequencing - Myeloproliferative Disorder | Unknown | Centre Hospitalier Universitaire de Nīmes | 30 | 2023-10-01 | 2024-02-07 | |
| Cord Blood Transplant in Adults With Blood Cancers Conditioning Chemotherapy, Cord blood graft - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2023-05-22 | 2026-10-23 |
| Haplo Peripheral Blood Sct In GVHD Prevention FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML | Phase 1 | Completed | Zachariah Michael DeFilipp | 25 | 2020-08-14 | 2025-07-20 |
| Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. Non-invasive diagnosis score - Myeloproliferative Disorder, Essential Thrombocythemia | Not applicable | Completed | University Hospital, Angers | 133 | 2019-07-30 | 2024-12-30 |
| Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms Aprepitant 80 mg, Hydroxyzine 25mg, Placebo of Hydroxyzine - Myeloproliferative Disorder, Aquagenic Pruritus | Phase 3 | Completed | University Hospital, Brest | 63 | 2019-04-16 | 2025-12-03 |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning Thymoglobulin, Melphalan, Fludarabine - Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes | Phase 2 | Recruiting | University of Liege | 114 | 2019-02-04 | 2022-10-12 |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Total body irradiation (TBI), Anti-thymocyte globulin (ATG), Tacrolimus - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | Stanford University | 22 | 2018-11-05 | 2023-12-12 |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase USDA Diet, Mediterranean Diet - Myeloproliferative Disorder, Myeloproliferative Syndrome | Not applicable | Completed | University of California, Irvine | 30 | 2018-10-01 | 2020-03-24 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 21 | 2018-03-28 | 2026-07-17 |
| Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 46 | 2018-02-07 | 2026-05-26 |
| Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) Isavuconazole - Hematologic Malignancy, Myeloproliferative Disorder | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 99 | 2017-05-04 | 2025-05-16 |
| Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms Myeloproliferative Disorder | Completed | University Hospital, Brest | 70 | 2013-07-17 | 2019-07-01 | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine Graft Manipulation (CD34+ Selection) - MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 41 | 2013-05-29 | 2020-07-21 |
| Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases echocardiography, right heart catheterisation - Myeloproliferative Disorder, Myelodysplastic Syndromes | Completed | Medical University of Graz | 86 | 2009-04-01 | 2012-03-09 | |
| Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders Myeloproliferative Disorder, MDS | Completed | Corewell Health West | 60 | 2008-04-01 | 2023-07-27 | |
| Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD IL-2 - Acute Lymphoblastic Leukemia, ALL | Phase 2 | Completed | Baylor College of Medicine | 25 | 2007-06-01 | 2018-05-04 |
| Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma Bevacizumab, Carboplatin, Gemcitabine - Myeloproliferative Disorder, Urothelial Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 51 | 2006-05-01 | 2016-01-22 |
| Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF - AML, ALL | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 25 | 2002-12-01 | 2016-07-18 |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Fludarabine, Melphalan, Stem cells - Acute Myelogenous Leukemia, Lymphoid Leukemia | Phase 2 | Completed | University of Chicago | 204 | 2001-11-01 | 2016-11-22 |
Showing 20 of 22. Sign in to see all of them.
Myeloproliferative Disorders (22) · Myelodysplastic Syndromes (10) · Leukemia, Myeloid, Acute (9) · Lymphoma, Non-Hodgkin (9) · Hodgkin Disease (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Primary Myelofibrosis (6) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Polycythemia Vera (4) · Anemia, Aplastic (3) · Blast Crisis (3) · Hematologic Neoplasms (3) · Lymphoma (3) · Multiple Myeloma (3)
Bone Marrow Diseases (22) · Hematologic Diseases (22) · Hemic and Lymphatic Diseases (22) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Leukemia (10) · Leukemia, Myeloid (10) · Chronic Disease (9) · Disease Attributes (9)
fludarabine (6) · Cyclophosphamide (4) · Melphalan (4) · Mycophenolic Acid (4) · Whole-Body Irradiation (3) · fludarabine phosphate (3) · Alemtuzumab (2) · Cyclosporine (2) · Granulocyte Colony-Stimulating Factor (2) · Tacrolimus (2) · thymoglobulin (2) · Antilymphocyte Serum (1) · Aprepitant (1) · Aspirin (1) · Base Sequence (1)
Memorial Sloan Kettering Cancer Center (4) · University Hospital, Brest (2) · Baylor College of Medicine (1) · Beth Israel Deaconess Medical Center (1) · Centre Hospitalier Universitaire de Nīmes (1) · Corewell Health West (1) · Dartmouth-Hitchcock Medical Center (1) · MPN Research Foundation (1) · Medical University of Graz (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Stanford University (1) · University Hospital, Angers (1) · University of California, Irvine (1) · University of Cambridge (1) · University of Chicago (1)
United States (15) · France (3) · Austria (1) · Belgium (1) · United Kingdom (1)
Andrew Artz, MD (1) · Angela G Fleischman, MD PhD (1) · Ann Jakubowski, MD (1) · Anthony R Green, Prof (1) · Arthur S Alberts, PhD (1) · Claire Harrison, Dr (1) · Damiano Rondelli, MD (1) · David E Avigan, MD (1) · David F McDermott, MD (1) · Dean Bajorin, MD (1) · Horst Olschewski, MD (1) · Ioannis Politikos, MD (1)
PMID 24573552, PMID 27291777, PMID 30153096, PMID 34923994, PMID 37877698, PMID 40423982
2017 (1), 2018 (1)